אפרקס 6000 - Eprex 6000: הבדלים בין גרסאות

Treatment of severe anemia associated with chronic renal failure, anemia in Zidovudine treated HIV infected patients, anemia in cancer patients on chemotherapy.To increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. Treatment is indicated in patients with moderate anemia (packed cell volume (PCV) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. Perisurgery: Reduction of allogeneic blood transfusion in surgery patients : Eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. Eprex is not indicated for anemic patients who are willing to donate autologous blood. The safety of the perioperative use of Eprex has been studied only in patients who are receiving anticoagulant prophylaxis. Eprex is indicated before surgeries known be associated with excessive blood loss (at least 2 units ).